Dianthus Therapeutics, Inc. (DNTH)
Dianthus Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York, NY, US. The stock last traded at $110.41, up 1.77% on the session, giving a market capitalisation of $6.18B. On trailing twelve-month figures it carries a trailing P/E of -849.27, a net margin of -1570.9%. Its beta of 0.08 implies it has historically moved less than the broad market.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Dianthus Therapeutics, Inc. is most often compared with the following Healthcare names: